Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?

Bone Marrow Transplantation volume 49, pages 1–7 (2014)Cite this article

Subjects

Abstract

Despite overall improvements in outcomes of patients with diffuse large B cell lymphoma (DLBCL), ∼30–40% of patients develop relapsed or refractory disease. For patients with chemo refractory disease, or recurrent disease following autologous hematopoietic SCT (auto-HCT), the prognosis is poor, with no consensus on the optimal therapy. Currently, owing to the graft vs lymphoma effect, hematopoietic allogeneic hematopoietic cell transplantation (allo-HCT) is the only potentially curative option for such patients. In addition, many patients who are considered today for auto-HCT actually have a low likelihood of benefit. For example, a patient with prior rituximab exposure who relapses within 1 year of diagnosis and has a second-line age-adjusted International Prognosis Index of 2 or 3 at relapse has a <25% chance of being cured by auto-HCT. It is possible that such patients may be better served with an allo-HCT. Unfortunately, in many cases, allo-HCT applicability is limited by patient age, comorbidities, performance status and treatment-related toxicities. Recent attempts to improve the efficacy of auto-HCT, such as incorporating radio-immunotherapy into the conditioning regimen, have not resulted in improved outcomes. However, incorporation of novel agents such as anti-programmed death-1 antibodies as maintenance therapy after auto-HCT show promise. Allo-HCT in relapsed/refractory DLBCL patients can result in a 30–40% PFS rate at 3 years, in part due to a graft vs DLBCL effect. While reduced-intensity/non-myeloablative conditioning is increasingly being used, certain patients may benefit from myeloablative conditioning. We present an algorithm intended to discriminate which relapsed and refractory DLBCL patients are most likely to benefit from auto-HCT vs allo-HCT. New approaches, using novel agents that target the molecular heterogeneity in DLBCL, will be an essential component of moving the field forward. Lastly, we propose a prospective registry-based study as the only feasible mechanism to define the optimal position of allo-HCT in the overall treatment strategy for DLBCL. It is hoped that this review will promote the development of prospective multicenter efforts to determine whether such patients do, in fact, benefit from earlier and/or more effective implementation of allo-HCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395–403.

    Article  Google Scholar 

  2. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426–432.

    Article  Google Scholar 

  3. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78–85.

    Article  Google Scholar 

  4. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342–1348.

    Article  Google Scholar 

  5. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012; 120: 4256–4262.

    Article  CAS  Google Scholar 

  6. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Impact of pretransplant conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsisve diffuse large B-cell lymphoma and grade-III follicular lymphoma. Biol Blood Marrow Transplant 2013; 19: 746–753.

    Article  Google Scholar 

  7. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010; 16: 35–45.

    Article  Google Scholar 

  8. Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol 2012; 91: 931–939.

    Article  Google Scholar 

  9. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  10. Gisselbrecht C, Glass B, Mounier N, Singh GD, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184–4190.

    Article  Google Scholar 

  11. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079–4087.

    Article  Google Scholar 

  12. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069–6076.

    Article  CAS  Google Scholar 

  13. Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 2011; 35: 183–187.

    Article  CAS  Google Scholar 

  14. Zhang H, Graiser M, Hutcherson DA, Dada MO, McMillan S, Ali Z et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1287–1294.

    Article  CAS  Google Scholar 

  15. Vose JM, Carter S, Burns LJ, Ayala E, Press O, Moskowitz CH et al. Phase III randomized study of rituximab/carmustin, etoposide, cytarabine, melphalan (BEAM) compared with 131-iodine tostitumomab/BEAM with autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0401 Trial. J Clin Oncol 2013; 31: 1662–1668.

    Article  CAS  Google Scholar 

  16. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 1653–1659.

    Article  CAS  Google Scholar 

  17. Krishnan A, Palmer JM, Tsai NC, Simpson JR, Nademanee A, Raubitschek A et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol Blood Marrow Transplant 2012; 18: 441–450.

    Article  Google Scholar 

  18. Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012; 118: 4706–4714.

    Article  CAS  Google Scholar 

  19. Gisselbrecht C, Schmitz N, Mounier N, Singh GD, Linch DC, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ Diffuse Large B-Cell Lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30: 4462–4469.

    Article  CAS  Google Scholar 

  20. Gordon L, Weller E, Armand P, Devine S, Holland H, Mason J et al. A Phase II study of CT-011, an anti-PD-1 antibody, after auSCT in recurrent/refractory DLBCL: first analysis of progression-free-survival (PFS), overall survival (OS) and toxicity (TOX). Ann Oncol 2011; 22 (Abstract 063).

  21. Lopez A, Gutierrez A, Palacios A, Blancas I, Navarrete M, Morey M et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008; 80: 127–132.

    Article  CAS  Google Scholar 

  22. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4371–4377.

    Article  CAS  Google Scholar 

  23. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28: 2085–2093.

    Article  CAS  Google Scholar 

  24. Cartron G, Thieblemont C, Solal-Celigny P, Morschhhauser F, Haioun C, Bouabdallah R et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patients - first results from a Phase II study in patients with relapsed/refractory DLBCL and MCL. Blood 2010; 116 (Abstract 2878).

  25. Coiffier B, Bosly A, Wu K, Verhoef G, Koen V, Martinelli G et al. Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a multicenter Phase II study. Blood 2010; 116 (Abstract 3955).

  26. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, LaCasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578–2585.

    Article  CAS  Google Scholar 

  27. Smith SM, van BK, Karrison T, Dancey J, McLaughlin P, Younes A et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740–4746.

    Article  CAS  Google Scholar 

  28. Barnes J, Jacobsen E, Feng Y, Freedman A, Hochberg E, LaCasce A et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Blood 2011; 118 (Abstract 1635).

  29. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622–1627.

    Article  CAS  Google Scholar 

  30. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117: 5058–5066.

    Article  CAS  Google Scholar 

  31. Jacobsen E, Advani R, Oki Y, Sharman J, Horwitz S, Forero-Torres A et al. A Phase 2 study of Brentuximab Vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin Lymphomas: interim results. Blood 2012; 120 (Abstract 2746).

  32. Ogura M, Ando K, Niitsu N, Kim S, Ohmachi K, Takahashi N et al. A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2012; 30 (Abstract 8023).

  33. Wilson WH, Gerecitano J, Goy A, de Vos S, Kenkre V, Barr P et al. The Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), has preferential activity in the ABC Subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open label, Phase II study. Blood 2012; 120 (Abstract 686).

  34. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: Results of a Phase I/II study evaluating the immunoconjugate Inotuzumab Ozogamicin with Rituximab. J Clin Oncol 2013; 31: 573–583.

    Article  CAS  Google Scholar 

  35. Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW et al. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2013; 54: 277–283.

    Article  CAS  Google Scholar 

  36. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW . Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 965–972.

    Article  Google Scholar 

  37. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005; 131: 223–230.

    Article  Google Scholar 

  38. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009; 15: 1455–1464.

    Article  CAS  Google Scholar 

  39. Grigg A, Ritchie D . Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004; 10: 579–590.

    Article  CAS  Google Scholar 

  40. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144–4152.

    Article  CAS  Google Scholar 

  41. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 2012; 119: 6373–6378.

    Article  CAS  Google Scholar 

  42. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008; 19: 1935–1940.

    Article  CAS  Google Scholar 

  43. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316.

    Article  CAS  Google Scholar 

  44. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407–4412.

    Article  CAS  Google Scholar 

  45. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419–2423.

    Article  Google Scholar 

  46. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865–3871.

    Article  CAS  Google Scholar 

  47. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535–3542.

    Article  CAS  Google Scholar 

  48. Butcher BW, Collins RH Jr . The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplant 2005; 36: 1–17.

    Article  CAS  Google Scholar 

  49. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835–1838.

    Article  CAS  Google Scholar 

  50. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411–2419.

    Article  CAS  Google Scholar 

  51. Durr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res 2010; 70: 10170–10181.

    Article  Google Scholar 

  52. Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012; 30: 3202–3208.

    Article  CAS  Google Scholar 

  53. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci 2013; 110: 1398–1403.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation, University Cancer Center Hamburg-Eppendorf, Hamburg, Germany

    E Klyuchnikov & U Bacher

  2. MLL Munich Leukemia Laboratory, Munich, Germany

    U Bacher

  3. Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

    T Kroll & T S Fenske

  4. Division of Hematology and Oncology, University of North Carolina, Chapel Hill, NC, USA

    T C Shea

  5. Division of Hematology-Oncology, Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA

    H M Lazarus

  6. Division of Hematology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada

    C Bredeson

Authors
  1. E Klyuchnikov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U Bacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Kroll
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T C Shea
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H M Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Bredeson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T S Fenske
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T S Fenske.

Ethics declarations

Competing interests

Professor Lazarus is an Editor for BMT. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klyuchnikov, E., Bacher, U., Kroll, T. et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?. Bone Marrow Transplant 49, 1–7 (2014). https://doi.org/10.1038/bmt.2013.72

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.72

Keywords

This article is cited by

Search

Advanced search

Quick links